Showing 1801-1810 of 5693 results for "".
- UK Surpasses Italy In Recorded Coronavirus Deaths, Now Leads Europe In Fatalitieshttps://modernod.com/news/uk-surpasses-italy-in-recorded-coronavirus-deaths-now-leads-europe-in-fatalities/2477715/Over 32,000 people have died from the new coronavirus in the United Kingdom, according to the Office for National Statistics, marking the first time in the pandemic that it has led Europe in the number of deaths, according to an NPR
- Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseaseshttps://modernod.com/news/boehringer-ingelheim-partners-with-inflammasome-therapeutics-to-develop-novel-therapies-for-patients-with-retinal-diseases/2476903/Boehringer Ingelheim and Inflammasome Therapeutics announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelhei
- Novartis Announces Details of TALON Global Clinical Trial in Wet AMD Comparing Brolucizumab vs Aflibercepthttps://modernod.com/news/novartis-announces-details-of-talon-global-clinical-trial-in-wet-amd-comparing-brolucizumab-vs-aflibercept/2476870/In the phase 3b TALON clinical trial, Novartis announced that the two primary endpoints are superiority for brolucizumab in treatment interval duration and noninferiority in change in visual acuity. Secondary endpoints will examine durability and anatomical outcomes, including retinal fluid resol
- Glaukos Announces Global Licensing Agreement With Intratus, Maker of Noninvasive Drug Delivery Platformhttps://modernod.com/news/glaukos-announces-global-licensing-agreement-with-intratus/2476756/Glaukos announced that it has entered into a licensing agreement with privately held, early-stage life sciences company Intratus. Under terms of the deal, Intratus has granted Glaukos a global exclusive license to
- Novel Approaches to Cataract Surgery are Challenging Phaco; Cost May Determine Their Successhttps://modernod.com/news/novel-approaches-to-cataract-surgery-are-challenging-phaco-cost-may-determine-their-success/2476591/Ultrasonic phacoemulsification (USP) has been the dominant method of cataract surgery globally over the past half century, but novel alternative approaches are attempting to improve or replace it, according to a Market Scope report. These include robotic cataract machines, ultrasonic-less
- SynergEyes Launches Tangible Hydra-PEG Coating on SynergEyes VS Scleral Lenshttps://modernod.com/news/synergeyes-launches-tangible-hydra-peg-coating-on-synergeyes-vs-scleral-lens/2476394/SynergEyes announced that the SynergEyes VS scleral lens is now available with Tangible Hydra-PEG on Contamac material. The Tangible Hydra-PEG coating is designed to solve the problem of contact lens discomfort and dry eyes by minimizing deposits and lens fogging, increasing lens surface water re
- Oyster Point Raises $93 Million to Support the Clinical Development of Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/oyster-point-raises-93-million-to-support-the-clinical-development-of-novel-treatment-for-dry-eye-disease/2476261/Oyster Point Pharma announced a $93 million Series B financing to support the development of its product portfolio for dry eye disease, explore new treatment areas, and add key talent. The company’s lead product candidates, OC-01 and OC-02, are delivered via an ocular surface-sparing nasal
- Astellas Announces Acquisition of Quethera, Maker of Gene Therapy Program for Glaucomahttps://modernod.com/news/astellas-announces-acquisition-of-quethera-maker-of-gene-therapy-program-for-glaucoma/2479949/Astellas Pharma has acquired Quethera, a gene therapy company headquartered in the United Kingdom that is focused on developing novel treatments for ocular disorders, such as glaucoma. Under the terms of the agreement, Astellas may pay up to £85 million ($1
- Aerie Pharmaceuticals and DSM Biomedical Expand Collaboration Agreement Focused on Novel Drug Delivery Technology in Ophthalmologyhttps://modernod.com/news/aerie-pharmaceuticals-and-dsm-biomedical-expand-collaboration-agreement-focused-on-novel-drug-delivery-technology-in-ophthalmology/2479966/Aerie Pharmaceuticals and DSM Biomedical reported that they have expanded their collaborative research, development, and license agreement. In July 2017, Aerie announced that it had entered into a research collaboration and license option agreement with DSM for purposes of evaluating the s
- RadianceTx Raises $1 Million First Tranche to Develop Novel Glaucoma Therapyhttps://modernod.com/news/radiancetx-raises-1-million-first-tranche-to-develop-novel-glaucoma-therapy/2479970/RadianceTx announced a $1 million first tranche closing of a targeted $7 million round of financing. The investment will be used to fund development of the company’s Beta Ophthalmic System for delivery of beta irradiation therapy to improve glaucoma surgery outcomes. Validated in three cli